RECRUITING

Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.

Conditions

Any Solid Oral Medication Solid oral medication

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication. The study will evaluate and monitor use of ReX in respect of: * treatment duration * adverse events * patient adherence and compliance * engagement with ReX via patient-reported outcomes Patients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients' responses to questions presented on the ReX touch screen.

Official Title

Non-randomized Observational Study to Collate Data Regarding the Safety, Efficacy and Satisfaction of ReX® in the Management of Solid Oral Medications.

Quick Facts

Study Start:2024-01-15

Study Completion:2026-01-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06335758

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. 18 years of age or older. 2. Care team recommends the use of ReX as a standard of care. 3. Patients have 5th grade reading level. 4. Patient was prescribed oral medication. 5. Patient takes medication at home.	1. Patient has significant physical disability including poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX dispensing unit effectively. 2. Patient failed to pass the learning module during ReX onboarding flow. 3. Patient is at end stage or terminal illness with anticipated life expectancy of 6 months or less.

Inclusion Criteria

Exclusion Criteria

1. 18 years of age or older.
2. Care team recommends the use of ReX as a standard of care.
3. Patients have 5th grade reading level.
4. Patient was prescribed oral medication.
5. Patient takes medication at home.

1. Patient has significant physical disability including poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX dispensing unit effectively.
2. Patient failed to pass the learning module during ReX onboarding flow.
3. Patient is at end stage or terminal illness with anticipated life expectancy of 6 months or less.

Contacts and Locations

Study Contact

Natan Paz

CONTACT

+972 52 6577126

natan.p@dosentrx.com

Principal Investigator

David Waterhouse, MD

PRINCIPAL_INVESTIGATOR

US Oncology

Study Locations (Sites)

OHC

Cincinnati, Ohio, 45242

United States

Collaborators and Investigators

Sponsor: Dosentrx Ltd.

David Waterhouse, MD, PRINCIPAL_INVESTIGATOR, US Oncology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-15

Study Completion Date2026-01-31

Study Record Updates

Study Start Date2024-01-15

Study Completion Date2026-01-31

Terms related to this study

Keywords Provided by Researchers

Solid oral medication

Additional Relevant MeSH Terms

Any Solid Oral Medication